Source: Drug Development Technology

Pivotal: Pivotal to support two trials of new immunotherapy for MM and NSCLC

Contract research organisation (CRO) Pivotal is set to support two Phase II clinical trials of a new immunotherapy drug in...Read More...The post Pivotal to support two trials of new immunotherapy for MM and NSCLC appeared first on Drug Development Technology.

Read full article »
Pivotal's Competitors | Pivotal's News | Pivotal's Financials
Stay up-to-date with the latest news on Pivotal SL
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Ibrahim Farr's photo - Chairman & CEO of Pivotal SL

Chairman & CEO

Ibrahim Farr

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Pivotal SL